Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 45 Breast Neoplasms 44 Precursor Cell Lymphoblastic Leukemia-Lymphoma 42 Lymphoma, Large B-Cell, Diffuse 41 Lymphoma, Non-Hodgkin 39 Multiple Myeloma 35 Leukemia 34 Leukemia, Lymphocytic, Chronic, B-Cell 32 Melanoma 31 Recurrence 29 Leukemia, Myeloid, Acute 28 Lymphoma, Follicular 27 Lymphoma, B-Cell 25 Ovarian Neoplasms 23 Lymphoma, Mantle-Cell 23 Neoplasm Metastasis 21 Hematologic Neoplasms 19 Myelodysplastic Syndromes 18 Hodgkin Disease 18 Pancreatic Neoplasms 17 Burkitt Lymphoma 16 Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Triple Negative Breast Neoplasms 12 Lymphoma, B-Cell, Marginal Zone 12 Colorectal Neoplasms 12 Stomach Neoplasms 11 Waldenstrom Macroglobulinemia 9 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9 Carcinoma, Hepatocellular 9

Interventions

vorolanib 1 fludarabine 1 Nivolumab 1 Cyclophosphamide 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Thymoma × Cyclophosphamide × Clear all

NCT07598955 2026-05-20

SELECT-NK-THYM

Beijing Biotech

Phase 1/2 Recruiting

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡